paclitaxel has been researched along with Intestinal Perforation in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akamaru, Y; Azama, T; Hokkoku, D; Ikeshima, R; Kitada, M; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R | 1 |
| Colombo, N; Donica, M; Dreosti, L; Estevez-Diz, M; Gonzalez-MartÃn, A; Irahara, N; Joly, F; Lorusso, D; McCormack, M; Nogueira-Rodrigues, A; Redondo, A; Ruff, P; Scambia, G; Schenker, M | 1 |
| Fujii, Y; Hirahara, N; Hyakudomi, R; Kaji, S; Tajima, Y; Taniura, T; Yamamoto, T | 1 |
| Bouffler, C; Chiong, C; El-Khoury, T; Jayakody, S; Liu, M; Wright, DB | 1 |
| Lan, SJ; Liu, ZC; Wang, DD; Wu, D | 1 |
| Buhr, HJ; Loddenkemper, C; Pohlen, U; Schellhaas, E; Schmittel, A | 1 |
| Fauvet, R; Gondry, J; Merviel, P; Mychaluk, J; Piprot, C; Sevestre, H | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA | 1 |
| Hensley, ML | 1 |
| Cohn, DE; Kim, KH; O'Malley, DM; Resnick, KE; Straughn, JM | 1 |
| Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L | 1 |
| Itamochi, H; Sato, S | 1 |
| Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H | 1 |
| Duan, Z; Hu, P; Yue, Y; Zhou, X | 1 |
| Matsui, H; Sekiya, S; Yamazawa, K | 1 |
| de Haan, D; van den Berg, M | 1 |
| Han, ES; Monk, BJ | 1 |
| Carter, J; Durfee, J | 1 |
| Piver, MS; Rose, PG | 1 |
| Cain, JM; Figge, DC; Greer, BE; Seewaldt, V; Tamimi, H | 1 |
4 review(s) available for paclitaxel and Intestinal Perforation
| Article | Year |
|---|---|
Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatal Outcome; Female; Humans; Intestinal Perforation; Intestine, Small; Middle Aged; Paclitaxel; Shock, Septic | 2018 |
Rectal perforation following paclitaxel and carboplatin chemotherapy for advanced ovarian cancer: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Intestinal Perforation; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Rectum | 2018 |
Bevacizumab and ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Hypertension; Intestinal Perforation; Ovarian Neoplasms; Paclitaxel; Proteinuria; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Bevacizumab in the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Hematologic Diseases; Humans; Intestinal Perforation; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salvage Therapy; Vascular Endothelial Growth Factor A | 2007 |
2 trial(s) available for paclitaxel and Intestinal Perforation
| Article | Year |
|---|---|
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Administration Schedule; Female; Humans; Incidence; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Uterine Cervical Neoplasms; Vaginal Fistula; Young Adult | 2020 |
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Administration Schedule; Eating; Feasibility Studies; Female; Fluorouracil; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2012 |
14 other study(ies) available for paclitaxel and Intestinal Perforation
| Article | Year |
|---|---|
[A Case of Gastric Cancer with Ramucirumab-Related Colon Perforation after a Subtotal Colectomy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Gastrectomy; Humans; Intestinal Perforation; Male; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2019 |
[A case of multiple intestinal perforation secondary to paclitaxel and carboplatin combined chemotherapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Intestinal Perforation; Lung Neoplasms; Paclitaxel | 2019 |
Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Intestinal Perforation; Lung Neoplasms; Male; Paclitaxel | 2009 |
[Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Ileal Neoplasms; Intestinal Perforation; Jejunal Neoplasms; Middle Aged; Paclitaxel | 2009 |
Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Hypertension; Incidence; Intestinal Perforation; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk | 2010 |
Big costs for little gain in ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Intestinal Perforation; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome | 2011 |
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Computer Simulation; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Intestinal Perforation; Models, Economic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine | 2011 |
A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Intestinal Perforation; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2012 |
Gastric perforation induced by combination chemotherapy in a patient with long-term use of corticosteroids.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cisplatin; Female; Humans; Intestinal Perforation; Middle Aged; Paclitaxel; Prednisolone; Taxoids; Time Factors; Uterine Neoplasms | 2002 |
Colonic perforation secondary to taxol therapy: an unusual presentation.
Topics: Antineoplastic Agents; Female; Humans; Intestinal Perforation; Middle Aged; Ovarian Neoplasms; Paclitaxel; Sigmoid Diseases | 2006 |
A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Intestinal Perforation; Necrosis; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel | 2007 |
Intestinal perforation secondary to paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Colonic Diseases; Female; Humans; Intestinal Perforation; Middle Aged; Paclitaxel | 1995 |
Bowel complications with taxol therapy.
Topics: Female; Humans; Intestinal Perforation; Ovarian Neoplasms; Paclitaxel | 1993 |